NASDAQHealth CareDiagnostics & ResearchSnapshot 2026-07-31
Reading FONR? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Daily closes. Earnings/event dots are placed inline.
Management is running behind on a stated commitment.
View ThesisRevenue is growing steadily — about 2% over the past year.
View GrowthManagement screens strong on capital allocation, margins.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is volatile — it swings about 0% on a typical day and fell roughly 14% in its worst 12-month stretch.
View RiskFONR's growth depends on strong financial performance and sector support. Recent performance has been strong, holding in the top half of its industry. It trades at typical peer multiples, but management is behind on commitments. If FONR cuts guidance, it could lead to a significant drop. Peer multiples imply a price about 12% above where it trades; this read is provisional.
Trailing returns as of 2026-06-05. FONR is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
A consensus fair price across 0 valuation methods, at three horizons. As of 2026-08-01. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Life Sciences Tools & Services — fair value, gap to price, and forward P/E.
Our valuation methods disagree too much on this name right now. Rather than print a number we don't believe, we're holding it back until they converge.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-06-05. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
